Reposted by Paddy Mark
TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
November 10, 2025 at 1:22 PM
TOM of this month goes to ACHIEVE trial (n=2,538), which showed that spironolactone 25 mg daily did not reduce CV events or mortality in dialysis patients, and increased risk of severe hyperkalemia #VA by
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
@nephromommy-akshu.bsky.social. See the latest #ISNTrialWatch summary for details.
Reposted by Paddy Mark
And another ns-MRA
Balcinrenone added to Dapa in proteinuric CKD
#KidneyWK
@thelancet.com
www.thelancet.com/journals/lan...
Balcinrenone added to Dapa in proteinuric CKD
#KidneyWK
@thelancet.com
www.thelancet.com/journals/lan...
Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinica...
In participants with chronic kidney disease at increased risk of disease progression,
a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin
alone in reducing albumin...
www.thelancet.com
November 8, 2025 at 6:18 PM
And another ns-MRA
Balcinrenone added to Dapa in proteinuric CKD
#KidneyWK
@thelancet.com
www.thelancet.com/journals/lan...
Balcinrenone added to Dapa in proteinuric CKD
#KidneyWK
@thelancet.com
www.thelancet.com/journals/lan...
Reposted by Paddy Mark
And the GBD analysis on CKD
From @paddymark.bsky.social and colleagues
www.thelancet.com/journals/lan... in @thelancet.com
#KidneyWk
From @paddymark.bsky.social and colleagues
www.thelancet.com/journals/lan... in @thelancet.com
#KidneyWk
Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
CKD is a major global health issue, with rising prevalence and increasing importance
as a cause of death and as a risk factor for cardiovascular death. A better understating
of aetiology, appropriate ...
www.thelancet.com
November 8, 2025 at 12:14 AM
And the GBD analysis on CKD
From @paddymark.bsky.social and colleagues
www.thelancet.com/journals/lan... in @thelancet.com
#KidneyWk
From @paddymark.bsky.social and colleagues
www.thelancet.com/journals/lan... in @thelancet.com
#KidneyWk
New Global Burden of Disease report on CKD. Up to 9th leading cause of mortality in adults 😢 #kidneyweek www.thelancet.com/action/showP...
www.thelancet.com
November 8, 2025 at 3:42 PM
New Global Burden of Disease report on CKD. Up to 9th leading cause of mortality in adults 😢 #kidneyweek www.thelancet.com/action/showP...
Reposted by Paddy Mark
Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Patients undergoing maintenance dialysis for kidney failure are at substantial risk of cardiovascular morbidity and mortality. We aimed to establish i…
www.sciencedirect.com
August 15, 2025 at 2:57 AM
Proud to have worked with colleagues and friends around the world on #ACHIEVE. We're disappointed spiro didn't prevent CV death/heart failure hospitalizations, but we've shown it's possible to do publicly funded large RCTs of repurposed meds in ESKD. More to do!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Paddy Mark
Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials
Mineralocorticoid receptor antagonists can prevent cardiovascular events in patients with heart failure and non-severe chronic kidney disease, but the…
www.sciencedirect.com
August 19, 2025 at 4:43 AM
Following #ACHIEVE our meta-analysis of RCTs of MRAs for pts receiving dialysis in @thelancet.com. Thanks to @lonniepyne.bsky.social for leading. No signal for benefit among low-risk of bias RCTs and a good demo of why we continue to need large simple trials.
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...